Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice.
Thomas KR, Allenspach EJ, Camp ND, Wray-Dutra MN, Khim S, Zielinska-Kwiatkowska A, Timms AE, Loftus JP, Liggitt HD, Georgopoulos K, Tasian SK, James RG, Rawlings DJ. Thomas KR, et al. Among authors: loftus jp. Leukemia. 2022 Jan;36(1):42-57. doi: 10.1038/s41375-021-01326-x. Epub 2021 Jun 30. Leukemia. 2022. PMID: 34193976 Free PMC article.
Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia.
Niswander LM, Loftus JP, Lainey É, Caye-Eude A, Pondrom M, Hottman DA, Iacobucci I, Mullighan CG, Jain N, Konopleva M, Cavé H, Baruchel A, Rohrlich PS, Tasian SK. Niswander LM, et al. Among authors: loftus jp. Haematologica. 2021 Oct 1;106(10):2763-2767. doi: 10.3324/haematol.2021.278697. Haematologica. 2021. PMID: 34196168 Free PMC article. No abstract available.
Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001).
Tasian SK, Silverman LB, Whitlock JA, Sposto R, Loftus JP, Schafer ES, Schultz KR, Hutchinson RJ, Gaynon PS, Orgel E, Bateman CM, Cooper TM, Laetsch TW, Sulis ML, Chi YY, Malvar J, Wayne AS, Rheingold SR. Tasian SK, et al. Among authors: loftus jp. Haematologica. 2022 Oct 1;107(10):2295-2303. doi: 10.3324/haematol.2021.279520. Haematologica. 2022. PMID: 35112552 Free PMC article. Clinical Trial.
Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3- mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia.
Niswander LM, Graff ZT, Chien CD, Chukinas JA, Meadows CA, Leach LC, Loftus JP, Kohler ME, Tasian SK, Fry TJ. Niswander LM, et al. Among authors: loftus jp. Haematologica. 2023 Feb 1;108(2):457-471. doi: 10.3324/haematol.2022.281456. Haematologica. 2023. PMID: 35950535 Free PMC article.
Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies.
Ang Z, Paruzzo L, Hayer KE, Schmidt C, Torres Diz M, Xu F, Zankharia U, Zhang Y, Soldan S, Zheng S, Falkenstein CD, Loftus JP, Yang SY, Asnani M, King Sainos P, Pillai V, Chong E, Li MM, Tasian SK, Barash Y, Lieberman PM, Ruella M, Schuster SJ, Thomas-Tikhonenko A. Ang Z, et al. Among authors: loftus jp. Blood. 2023 Nov 16;142(20):1724-1739. doi: 10.1182/blood.2023020400. Blood. 2023. PMID: 37683180 Free PMC article.
61 results